Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis

Sponsor

National University Hospital, Singapore (Other)

Overall Status

Unknown status

CT.gov ID

NCT01638520

Collaborator

National University, Singapore (Other)

Enrollment

Locations

Arms

Duration (Months)

4.6

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

New approaches are needed to achieve more rapid elimination of dormant mycobacteria and thereby shorten treatment for drug-sensitive and drug-resistant tuberculosis (TB). Dormant mycobacteria are relatively resistant to antibacterial drugs and approaches that enhance immune clearance have the potential to be more effective. Interleukin-4 (IL-4) is a key cytokine in the immune response to TB that may impair the clearance of mycobacteria. We hypothesize that pascolizumab, an anti-IL-4 monoclonal antibody, might be of value as an adjunct to standard treatment.

The aims of this trial are to determine whether administration of pascolizumab as an adjunct to standard combination treatment for drug-sensitive TB produces changes in one or more parameters of bacterial or host response (including bacterial clearance, host clinical status, immune response, bacterial and host transcriptomics, lung imaging) that may indicate potential for enhanced sterilization and to confirm the safety of blocking IL-4 (previously demonstrated in healthy volunteers and patients with asthma) in patients with TB.

Condition or Disease	Intervention/Treatment	Phase
Tuberculosis, Pulmonary	Drug: Pascolizumab Drug: Placebo	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

32 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB): a Randomized, Double-blind, Placebo-controlled, Proof-of-concept Clinical Trial

Study Start Date :

Jun 1, 2012

Actual Primary Completion Date :

Feb 1, 2017

Anticipated Study Completion Date :

Jul 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Pascolizumab The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.	Drug: Pascolizumab 0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
Placebo Comparator: Placebo For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.	Drug: Placebo Saline (volume determined based on weight of patient, and cohort of enrollment)

Arm

Intervention/Treatment

Experimental: Pascolizumab

The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.

Drug: Pascolizumab

0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort

Placebo Comparator: Placebo

For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.

Drug: Placebo

Saline (volume determined based on weight of patient, and cohort of enrollment)

Outcome Measures

Primary Outcome Measures

Efficacy - Time to detection on liquid culture of sputum on Week 8 [8 weeks post intervention]
Co-primary outcome measure - safety [Upto 24 weeks via follow-up visits/assessments and 24-96 weeks via phone assessments]
Adverse events considered at least possibly related to study medication and that are classified by the site investigator as serious and/or grade IV severity

Secondary Outcome Measures

Sputum culture status (positive or negative) on liquid culture at week 8 [8 weeks]
Rate of change (area under the curve) from baseline to week 8 in the time to positivity in liquid culture of sputum [8 weeks]
Rate of change in serial sputum colony counts on solid cultures from baseline to week 8 [8 weeks]
Rate of change of RPF-dependent serial sputum colony counts from baseline to week 8 [8 weeks]
Sputum culture status (positive or negative) on solid culture at week 8 [8 weeks]
Rate of change of sputum smear lipid-body positive mycobacteria from baseline to week 8 [8 weeks]
Serum IL-4 levels (free and drug-bound) [24 weeks]
Time to resolution of fever [24 weeks]
Time to resolution of all TB symptoms [24 weeks]
Resolution of chest X-ray changes at week 24 [24 weeks]
Resolution of PET/MRI changes at week 8 and week 24 [24 weeks]
TB relapse at any time up to week 96 [96 weeks]
Anti-pascolizumab antibodies [24 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

21 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Aged 21 -75 years of age
Male or female: females eligible only if not of childbearing potential or agree to remain abstinent or use an appropriate contraceptive method during the study.
Confirmed pulmonary TB by smear microscopy and Gene Xpert™
Absence of rifampicin resistance on molecular probe (Gene Xpert™)
Estimated to be able to produce at least 5ml of sputum per 24 hour period.
No previous history of anti-TB therapy for active disease (treatment for latent disease acceptable).
Willing to comply with the study visits and procedures
Willing and able to provide written informed consent

Exclusion Criteria:

More than 28 days of standard anti-TB chemotherapy at the time of randomization.
Disseminated TB (lymphadenopathy is acceptable)
Underlying serious chronic diseases such as those of the liver, kidney disease, blood disorders and Type I diabetes (controlled Type II diabetes is acceptable) or any significant organ dysfunction.
History of myocardial infarction, congestive heart failure or arrhythmia within 6 months of screening
History or evidence of chronic alcohol consumption or drug abuse
Current autoimmune disease or history of autoimmune disease.
Known or suspected hypersensitivity to any component of the trial medication (sodium phosphate, sodium chloride, glycine, sucrose, polysorbate 80)
Chronic use of an immunosuppressant
Treatment with any monoclonal antibody within 6 months of randomization
Vaccination within the 6 weeks prior to randomization (patients who have received influenza vaccination can enroll at 2 weeks following vaccination).
Seropositive for human immunodeficiency virus-1 or 2; hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies at screening
Creatinine > 1.4 times upper limit of normal or ALT greater than 2.5 times upper limit of normal on screening blood tests
QTc >450 msec on ECG performed at screening
Women who are currently pregnant or breastfeeding
Any other significant condition that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial.
Participation in other clinical intervention trial or research protocol (Participation in other studies that do not involve an intervention may be allowed, but this must be discussed and approved by Chief Investigator )

Contacts and Locations

Locations

	Site	City	Country
1	Institute of Respiratory Medicine	Kuala Lumpur	Malaysia
2	University Malaya Medical Centre	Kuala Lumpur	Malaysia
3	Lung Centre Philippines	Manila	Philippines
4	Philippines Tuberculosis Society Inc.	Manila	Philippines
5	Changi General Hospital	Singapore	Singapore
6	National University Hospital, Singapore	Singapore	Singapore
7	Ng Teng Fong General Hospital	Singapore	Singapore